GT Biopharma, Inc.
GTBP
$5.98
$0.7414.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 110.35% | 48.93% | 4.48% | -23.17% | -23.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.10% | 1.01% | -13.52% | -23.09% | -18.63% |
| Operating Income | -51.10% | -1.01% | 13.52% | 23.09% | 18.63% |
| Income Before Tax | 12.16% | -406.74% | -333.75% | -206.37% | -235.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 12.16% | -406.74% | -333.75% | -206.37% | -235.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.16% | -406.74% | -333.75% | -206.37% | -235.84% |
| EBIT | -51.10% | -1.01% | 13.52% | 23.09% | 18.63% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 77.27% | -147.15% | -104.07% | -83.77% | -87.11% |
| Normalized Basic EPS | 81.30% | -121.16% | -102.74% | -88.46% | -92.07% |
| EPS Diluted | 77.27% | -147.15% | -104.07% | -83.77% | -87.11% |
| Normalized Diluted EPS | 81.30% | -121.16% | -102.74% | -88.46% | -92.07% |
| Average Basic Shares Outstanding | 795.24% | 484.47% | 190.53% | 68.68% | 64.48% |
| Average Diluted Shares Outstanding | 795.24% | 484.47% | 190.53% | 68.68% | 64.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |